Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Prime Medicine Inc (PRME)

Prime Medicine Inc (PRME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference GlobeNewswire - Wed Jun 3, 7:00AM CDT

CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.06 (-11.82%)
Prime Medicine to Present at Jefferies Global Healthcare Conference GlobeNewswire - Thu May 28, 7:00AM CDT

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.06 (-11.82%)
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire - Thu May 7, 7:00AM CDT

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 --   -- Continued regulatory...

PRME : 3.06 (-11.82%)
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer GlobeNewswire - Thu Apr 16, 7:00AM CDT

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.06 (-11.82%)
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire - Tue Mar 3, 7:00AM CST

-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for...

PRME : 3.06 (-11.82%)
Prime Medicine to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 25, 7:00AM CST

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.06 (-11.82%)
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Jan 7, 7:00AM CST

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.06 (-11.82%)
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease GlobeNewswire - Sun Dec 7, 2025

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.06 (-11.82%)
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.06 (-11.82%)
Prime Medicine to Present at Jefferies Global Healthcare Conference GlobeNewswire - Tue Nov 11, 2025

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.06 (-11.82%)

Barchart Exclusives

Tesla Sales in China Are Popping, But That Means Nothing If You Can’t Stomach TSLA Stock’s Absurd P/E Ratio Barchart - Sat Jun 6, 3:00PM CDT
Tesla China sales jumped almost 40% in May as its FSD software rolled out globally. Here's why TSLA stock still belongs on your watch list now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.